Search

Your search keyword '"Iftode C"' showing total 270 results
Start Over Author "Iftode C"
270 results on '"Iftode C"'

6. Viral DNA synthesis-dependent titration of a cellular repressor activates transcription of the human adenovirus type 2 [IVa.sub.2] gene

Author

Iftode, C. and Flint, S.J.

Subjects
Adenoviruses, Human -- Analysis, DNA synthesis -- Forecasts and trends, Market trend/market analysis, Science and technology
Abstract

Synthesis of progeny DHA genomes in cells infected by human subgroup C adenoviruses leads to several changes in viral gene expression. These changes include transcription from previously silent, late promoters, such as the I[V.sub.a2] promoter, and a large increase in the efficiency of major-late (ML) transcription. Some of these changes appear to take place sequentially, because the product of the I[V.sub.a2] gene has been implicated in stimulation of ML transcription. Our previous biochemical studies suggested that I[V.sub.a2] transcription is regulated by viral DNA synthesis-dependent relief of transcriptional repression by a cellular protein that we termed I[V.sub.a2]-RF. To test the relevance of such a repressor-titration mechanism during the viral infectious cycle, we introduced into the endogenous I[V.sub.a2] promoter two mutations that impair in vitro-binding of I[V.sub.a2]-RF, but introduce no change (Rep7) or one conservative amino acid substitution (Rep6) into the overlapping coding sequence for the viral DNA polymerase. The results of run-on transcription assays indicated that both mutations induced earlierthan-normal and more efficient I[V.sub.a2] transcription. Both mutations were also observed to result in modest increases in the efficiency of viral DNA synthesis. However, measurement of the concentration of I[V.sub.a2] transcripts as a function of I[V.sub.a2] template concentration demonstrated that the Rep mutations increased by up to 60-fold the efficiency with which I[V.sub.a2] templates were used during the initial period of the late phase of infection, as predicted by the repressor titration hypothesis. These mutations also increased the efficiency of ML transcription in infected cells. late transcription | repressor titration

Published
2004

7. The IFRS 17 contractual service margin: a life insurance perspective

Author

Yousuf, W., primary, Stansfield, J., additional, Malde, K., additional, Mirin, N., additional, Walton, R., additional, Thorpe, B., additional, Thorpe, J., additional, Iftode, C., additional, Tan, L., additional, Dyble, R., additional, Pelsser, A., additional, Ghosh, A., additional, Qin, W., additional, Berry, T., additional, and Er, C., additional

Published
2021
Full Text
View/download PDF

9. PO-0952: Hypofractionated WBI in large-breasted patients: long-term toxicity of a prospective series

Author

De Rose, F., primary, Fogliata, A., additional, Franceschini, D., additional, Iftode, C., additional, D'Agostino, G.R., additional, Comito, T., additional, Franzese, C., additional, Di Brina, L., additional, Clerici, E., additional, Loi, M., additional, Navarria, P., additional, Gatzemeier, W., additional, Testori, A., additional, Tinterri, C., additional, Lobefalo, F., additional, Tomatis, S., additional, and Scorsetti, M., additional

Published
2020
Full Text
View/download PDF

11. Stereotactic rt in ovarian cancer: multicentric retrospective pooled analysis (MITO-RT project)

Author

Macchia, G, D'Agostino, Gr, Fodor, A, Cerrotta, Am, Autorino, R, Russo, D, Perrucci, E, Zamagni, A, Di Stefano, A, Iftode, C, Cilla, S, Morganti, Ag, Aristei, C, Di Muzio, N, Scorsetti, M, Deodato, F, Scambia, G, Valentini, V, and Ferrandina, G

Subjects
Nuclear Medicine & Medical Imaging, Oncology, Radiology, Nuclear Medicine & Medical Imaging, Radiology
Published
2019

12. EP-1282 Postmastectomy radiation therapy using VMAT for breast cancer patients with expander reconstructions

Author

De Rose, F., primary, Fogliata, A., additional, Franceschini, D., additional, Iftode, C., additional, Cozzi, S., additional, Stravato, A., additional, Masci, G., additional, Torrisi, R., additional, Testori, A., additional, Tinterri, C., additional, Lisa, A.V.E., additional, Veronesi, A., additional, Giannasi, S., additional, Klinger, M., additional, and Scorsetti, M., additional

Published
2019
Full Text
View/download PDF

13. EP-1482 Stereotactic rt in ovarian cancer: multicentric retrospective pooled analysis (MITO-RT project)

Author

Macchia, G., primary, D'Agostino, G.R., additional, Fodor, A., additional, Cerrotta, A.M., additional, Autorino, R., additional, Russo, D., additional, Perrucci, E., additional, Zamagni, A., additional, Di Stefano, A., additional, Iftode, C., additional, Cilla, S., additional, Morganti, A.G., additional, Aristei, C., additional, Di Muzio, N., additional, Scorsetti, M., additional, Deodato, F., additional, Scambia, G., additional, Valentini, V., additional, and Ferrandina, G., additional

Published
2019
Full Text
View/download PDF

14. EP-1457 Moderate hypofractionation and SIB with volumetric modulated arc therapy (RapidArc) for anal cancer

Author

Tozzi, A., primary, Iftode, C., additional, Cozzi, S., additional, D'Agostino, G.R., additional, Franzese, C., additional, Di Brina, L., additional, Comito, T., additional, De Rose, F., additional, Renna, I., additional, Franceschini, D., additional, Navarria, P., additional, Clerici, E., additional, Mancosu, P., additional, Lobefalo, F., additional, Stravato, A., additional, and Scorsetti, M., additional

Published
2019
Full Text
View/download PDF

16. PO-0740 Can HSRS on tumor bed replace WBRT in resected brain metastases? Results of a phase II study

Author

Navarria, P., primary, Clerici, E., additional, Franzese, C., additional, D’Agostino, G.R., additional, Comito, T., additional, De Rose, F., additional, Franceschini, D., additional, Iftode, C., additional, Tozzi, A., additional, Pessina, F., additional, Bello, L., additional, Cozzi, S., additional, Renna, I., additional, Di Brina, L., additional, and Scorsetti, M., additional

Published
2019
Full Text
View/download PDF

18. Patient Characteristics and General Practitioners' Advice to Stop Statins in Oldest-Old Patients: a Survey Study Across 30 Countries

Author

Ploeg, M.A., Streit, S., Achterberg, W.P., Beers, E., Bohnen, A.M., Burman, R.A., Collins, C., Franco, F.G., Gerasimovska-Kitanovska, B., Gintere, S., Bravo, R. Gomez, Hoffmann, K., Iftode, C., Pestic, S.K., Koskela, T.H., Kurpas, D., Maisonneuve, H., Mallen, C.D., Merlo, C., Mueller, Y., Muth, C., Petrazzuoli, F., Rodondi, N., Rosemann, T., Sattler, M., Schermer, T.R., Ster, M.P., Svadlenkova, Z., Tatsioni, A., Thulesius, H., Tkachenko, V., Torzsa, P., Tsopra, R., Tuz, C., Vaes, B., Viegas, R.P.A., Vinker, S., Wallis, K.A., Zeller, A., Gussekloo, J., Poortvliet, R.K.E., Ploeg, M.A., Streit, S., Achterberg, W.P., Beers, E., Bohnen, A.M., Burman, R.A., Collins, C., Franco, F.G., Gerasimovska-Kitanovska, B., Gintere, S., Bravo, R. Gomez, Hoffmann, K., Iftode, C., Pestic, S.K., Koskela, T.H., Kurpas, D., Maisonneuve, H., Mallen, C.D., Merlo, C., Mueller, Y., Muth, C., Petrazzuoli, F., Rodondi, N., Rosemann, T., Sattler, M., Schermer, T.R., Ster, M.P., Svadlenkova, Z., Tatsioni, A., Thulesius, H., Tkachenko, V., Torzsa, P., Tsopra, R., Tuz, C., Vaes, B., Viegas, R.P.A., Vinker, S., Wallis, K.A., Zeller, A., Gussekloo, J., and Poortvliet, R.K.E.

Abstract

Contains fulltext : 208370.pdf (publisher's version ) (Open Access), BACKGROUND: Statins are widely used to prevent cardiovascular disease (CVD). With advancing age, the risks of statins might outweigh the potential benefits. It is unclear which factors influence general practitioners' (GPs) advice to stop statins in oldest-old patients. OBJECTIVE: To investigate the influence of a history of CVD, statin-related side effects, frailty and short life expectancy, on GPs' advice to stop statins in oldest-old patients. DESIGN: We invited GPs to participate in this case-based survey. GPs were presented with 8 case vignettes describing patients > 80 years using a statin, and asked whether they would advise stopping statin treatment. MAIN MEASURES: Cases varied in history of CVD, statin-related side effects and frailty, with and without shortened life expectancy (< 1 year) in the context of metastatic, non-curable cancer. Odds ratios adjusted for GP characteristics (ORadj) were calculated for GPs' advice to stop. KEY RESULTS: Two thousand two hundred fifty GPs from 30 countries participated (median response rate 36%). Overall, GPs advised stopping statin treatment in 46% (95%CI 45-47) of the case vignettes; with shortened life expectancy, this proportion increased to 90% (95CI% 89-90). Advice to stop was more frequent in case vignettes without CVD compared to those with CVD (ORadj 13.8, 95%CI 12.6-15.1), with side effects compared to without ORadj 1.62 (95%CI 1.5-1.7) and with frailty (ORadj 4.1, 95%CI 3.8-4.4) compared to without. Shortened life expectancy increased advice to stop (ORadj 50.7, 95%CI 45.5-56.4) and was the strongest predictor for GP advice to stop, ranging across countries from 30% (95%CI 19-42) to 98% (95% CI 96-99). CONCLUSIONS: The absence of CVD, the presence of statin-related side effects, and frailty were all independently associated with GPs' advice to stop statins in patients aged > 80 years. Overall, and within all countries, cancer-related short life expectancy was the strongest independent predictor of GPs' advice

Published
2019

19. Patient Characteristics and General Practitioners' Advice to Stop Statins in Oldest-Old Patients: a Survey Study Across 30 Countries

Author

Ploeg, M.A. (Milly) van der, Streit, S., Achterberg, W.P., Beers, E., Bohnen, A.M. (Arthur), Burman, R.A., Collins, C. (Colin), Franco, F.G., Gerasimovska-Kitanovska, B., Gintere, S., Bravo, R.G., Hoffmann, K., Iftode, C., Pestic, S.K., Koskela, T.H., Kurpas, D., Maisonneuve, H., Mallen, C.D., Merlo, C., Mueller, Y., Muth, C., Petrazzuoli, F., Rodondi, N, Rosemann, T., Sattler, M., Schermer, T., Ster, M.P., Svadlenkova, Z., Tatsioni, A., Thulesius, H., Tkachenko, V. (Valery), Torzsa, P., Tsopra, R., Tuz, C., Vaes, B., Viegas, R.P.A., Vinker, S., Wallis, K.A., Zeller, A., Gussekloo, J. (Jacobijn), Poortvliet, R.K.E., Ploeg, M.A. (Milly) van der, Streit, S., Achterberg, W.P., Beers, E., Bohnen, A.M. (Arthur), Burman, R.A., Collins, C. (Colin), Franco, F.G., Gerasimovska-Kitanovska, B., Gintere, S., Bravo, R.G., Hoffmann, K., Iftode, C., Pestic, S.K., Koskela, T.H., Kurpas, D., Maisonneuve, H., Mallen, C.D., Merlo, C., Mueller, Y., Muth, C., Petrazzuoli, F., Rodondi, N, Rosemann, T., Sattler, M., Schermer, T., Ster, M.P., Svadlenkova, Z., Tatsioni, A., Thulesius, H., Tkachenko, V. (Valery), Torzsa, P., Tsopra, R., Tuz, C., Vaes, B., Viegas, R.P.A., Vinker, S., Wallis, K.A., Zeller, A., Gussekloo, J. (Jacobijn), and Poortvliet, R.K.E.

Abstract

BACKGROUND: Statins are widely used to prevent cardiovascular disease (CVD). With advancing age, the risks of statins might outweigh the potential benefits. It is unclear which factors influence general practitioners’ (GPs) advice to stop statins in oldestold patients. OBJECTIVE: To investigate the influence of a history of CVD, statin-related side effects, frailty and short life expectancy, on GPs’ advice to stop statins in oldest-old patients. DESIGN: We invited GPs to participate in this case-based survey. GPs were presented with 8 case vignettes describing patients > 80 years using a statin, and asked whether they would advise stopping statin treatment. MAIN MEASURES: Cases varied in history of CVD, statinrelated side effects and frailty, with and without shortened life expectancy (< 1 year) in the context of metastatic, noncurable cancer. Odds ratios adjusted for GP characteristics (ORadj) were calculated for GPs’ advice to stop. KEY RESULTS: Two thousand two hundred fifty GPs from 30 countries participated (median response rate 36%). Overall, GPs advised stopping statin treatment in 46% (95%CI 45–47) of the case vignettes; with shortened life expectancy, this proportion increased to 90% (95CI% 89–90). Advice to stop was more frequent in case vignettes without CVD compared to those with CVD (ORadj 13.8, 95%CI 12.6–15.1), with side effects compared to without ORadj 1.62 (95%CI 1.5–1.7) and with frailty (ORadj 4.1, 95%CI 3.8–4.4) compared to without. Shortened life expectancy increased advice to stop (ORadj 50.7, 95%CI 45.5–56.4) and was the strongest predictor for GP advice to stop, ranging across countries from 30% (95%CI 19– 42) to 98% (95% CI 96–99). CONCLUSIONS: The absence of CVD, the presence of statin-related side effects, and frailty were all independently associated with GPs’ advice to stop statins in patients aged > 80 years. Overall, and within all countries, cancer-related short life expectancy was the strongest independent predictor of GPs’ advice t

Published
2019
Full Text
View/download PDF

20. Patient Characteristics and General Practitioners' Advice to Stop Statins in Oldest-Old Patients: a Survey Study Across 30 Countries

Author

Ploeg, Milly, Streit, S, Achterberg, WP, Beers, E, Bohnen, Arthur, Burman, RA, Collins, C, Franco, FG, Gerasimovska-Kitanovska, B, Gintere, S, Bravo, RG, Hoffmann, K, Iftode, C, Pestic, SK, Koskela, TH, Kurpas, D, Maisonneuve, H, Mallen, CD, Merlo, C, Mueller, Y, Muth, C, Petrazzuoli, F, Rodondi, N, Rosemann, T, Sattler, M, Schermer, T, Ster, MP, Svadlenkova, Z, Tatsioni, A, Thulesius, H, Tkachenko, V, Torzsa, P, Tsopra, R, Tuz, C, Vaes, B, Viegas, RPA, Vinker, S, Wallis, KA, Zeller, A, Gussekloo, J, Poortvliet, RKE, Ploeg, Milly, Streit, S, Achterberg, WP, Beers, E, Bohnen, Arthur, Burman, RA, Collins, C, Franco, FG, Gerasimovska-Kitanovska, B, Gintere, S, Bravo, RG, Hoffmann, K, Iftode, C, Pestic, SK, Koskela, TH, Kurpas, D, Maisonneuve, H, Mallen, CD, Merlo, C, Mueller, Y, Muth, C, Petrazzuoli, F, Rodondi, N, Rosemann, T, Sattler, M, Schermer, T, Ster, MP, Svadlenkova, Z, Tatsioni, A, Thulesius, H, Tkachenko, V, Torzsa, P, Tsopra, R, Tuz, C, Vaes, B, Viegas, RPA, Vinker, S, Wallis, KA, Zeller, A, Gussekloo, J, and Poortvliet, RKE

Published
2019

31. External validation of multidimensional prognostic indices (ADO, BODEx and DOSE) in a primary care international cohort (PROEPOC/COPD cohort)

Author

Espantoso-Romero, M., Román Rodríguez, M., Duarte-Pérez, A., Gonzálvez-Rey, J., Callejas-Cabanillas, P., Lazic, D.K., Anta-Agudo, B., Torán Monserrat, P., Magallon-Botaya, R., Gerasimovska Kitanovska, B., Lingner, H., Assenova, R.S., Iftode, C., Gude-Sampedro, F., Clavería, A., Abalde-Castro, L., Ares-Vila, S., Bernardez-Peña, L.N., Bozhinovska, E., Budiu, I., Bundó Vidiella, M., Clemente-Jimenez, L., Coma Carbó, R.M., Del Río-Navarro, C., Erazo, S., Góngora Andrades, M.A., Gorreto López, L., Hamulka, D., Hernández-Rodríguez, A., Hristeva Foreva, G., Jovanovska, S., Lazic, A., Martín-Campos, C., Mayrata, A., Montero Alia, P., Negrete Palma, A., Núñez-Chicharro, L., Padure, I., Palmer Simó, J.F., Pérez-Villar, M.V., Rego-Sieiro, E., Robles Sánchez, C., Rodríguez-Reneda, L., Schmiemann, G., Sorribes Lopez, J., Spasovska, A., Stanic, J., Stefanescu, S., Tiljak, A., Valero Suau, A., Vila Rigat, R., Volkenand, K., and Wöbkenberg, J.

Abstract

Background: Due to the heterogeneous and systemic nature of the chronic obstructive pulmonary disease (COPD), the new guidelines are oriented toward individualized attention. Multidimensional scales could facilitate its proper clinical and prognostic assessment, but not all of them were validated in an international primary care cohort, different from the original ones used for model development. Therefore, our main aim is to assess the prognostic capacity of the ADO, BODEx and DOSE indices in primary care for predicting mortality in COPD patients and to validate the models obtained in subgroups of patients, classified by revised Global Initiative for Chronic Obstructive Lung Disease (2011) and updated Spanish Guideline (2014). Besides, we want to confirm that the prognostic capacity of all indices increases if the number of exacerbations is substituted by the interval between them and to assess the impact on health of the patient''s lifestyle, social network and adherence to treatment. Methods: Design: External validation of scales, open and prospective cohort study in primary care. Setting: 36 health centres in 6 European high, medium and low income countries. Subjects: 477 patients diagnosed with COPD, captured in clinical visit by their General Practitioner/Nurse. Predictors: Detailed patient history, exacerbations, lung function test and questionnaires at baseline. Outcomes: Exacerbations, all-cause mortality and specific mortality, within 5 years of recruitment. Analysis: Multivariate logistic regression and Cox regression will be used. Possible non-linear effect of the indices will be studied by using Structured Additive Regression models with penalised splines. Subsequently, we will assess different aspects of the regression models: discrimination, calibration and diagnostic precision. Clinical variables modulated in primary care and the interval between exacerbations will be considered and incorporated into the analysis. Discussion: The Research Agenda for General Practice/Family Medicine highlights that the evidence on predictive values of prognostic indices in primary care is scarce. A prospective cohort like that of PROEPOC/COPD provides good opportunities for research into COPD and make communication easier between family practitioners, nursing staff, pneumologists and other professionals, supporting a multi-disciplinary approach to the treatment of these patients. Trial registration:ISRCTN52402811. Date: 15/01/2015. Prospectively registered.

Published
2017

32. Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study.

Author

Alongi, F, Cozzi, L, Arcangeli, S, Iftode, C, Comito, T, Villa, E, Lobefalo, F, Navarria, P, Reggiori, G, Mancosu, P, Clerici, E, Fogliata, A, Tomatis, S, Taverna, G, Graziotti, P, Scorsetti, M, Alongi F, Cozzi L, Arcangeli S, Iftode C, Comito T, Villa E, Lobefalo F, Navarria P, Reggiori G, Mancosu P, Clerici E, Fogliata A, Tomatis S, Taverna G, Graziotti P, Scorsetti M., Alongi, F, Cozzi, L, Arcangeli, S, Iftode, C, Comito, T, Villa, E, Lobefalo, F, Navarria, P, Reggiori, G, Mancosu, P, Clerici, E, Fogliata, A, Tomatis, S, Taverna, G, Graziotti, P, Scorsetti, M, Alongi F, Cozzi L, Arcangeli S, Iftode C, Comito T, Villa E, Lobefalo F, Navarria P, Reggiori G, Mancosu P, Clerici E, Fogliata A, Tomatis S, Taverna G, Graziotti P, and Scorsetti M.

Abstract

BACKGROUND: To evaluate the feasibility and early side effects of a short course hypo-fractionated SBRT programme with Volumetric Modulated Arc Therapy (VMAT) and Flattening Filter Free (FFF) beams. METHODS: A prospective phase I-II study, started on February 2012. Inclusion criteria were: age <= 80 years, WHO-PS <= 2, PSA <= 20 ng/ml, histologically proven prostate adenocarcinoma, T1-T2 stage, no distant metastases, no previous surgery other than TURP, no malignant tumours in the previous 5 years, IPSS 0--7. The schedule was 35Gy in 5 alternative days. SBRT was delivered with RapidArc VMAT, with 10MV FFF photons. Toxicity assessment was performed according to CTCAE v4.0 scale. EPIC questionnaires assessed Quality-of-Life.. Neo-adjuvant/concomitant hormonal-therapy was prescribed according to risk classification. SpaceOARTM gel was optionally implanted to increase the separation space between the prostate and the rectal wall. RESULTS: Median follow-up was 11 months (range: 5--16); 40 patients were recruited in the protocol and treated.. According to NCCN criteria, 26/40 patients were low-risk and 14/40 were intermediate risk. Median age was 70 years (56--80), median initial PSA was 6.25 ng/ml (0.50-13.43 ng/ml). Median Gleason score was 6 (6--7). All patients completed the treatment as programmed (median 11.8 days (9--22). Acute Toxicities were as follow: Rectum G0: 30/40 cases (75%); G1: 6/40 (15%); G2: 4/40 (10%). Genito-urinary: G0: 16/40 (40%); G1: 8/40 (20%); G2: 16/34 (40%). In two G2 urinary retention cases, intermittent catheter was needed. No acute G3 or greater toxicity was found. Median treatment time was 126 sec (120--136). SpaceOARTM was implanted in 8 patients. PSA reduction from the pre-treatment value of the marker was documented in all patients. CONCLUSIONS: Early findings suggest that SBRT with RapidArc and FFF beams for prostate cancer in 5 fractions is feasible and tolerated in acute setting. Longer follow-up is needed for assessment of

Published
2013

33. Linac Based SBRT for prostate cancer in five fractions: preliminary report of a Phase II Study with FFF delivery

Author

Alongi, F, Iftode, C, Arcangeli, S, Villa, E, Liardo, L, Tozzi, A, Mancosu, P, Tomatis, S, Cozzi, L, Scorsetti, M, Alongi F, Iftode C, Arcangeli S, Villa E, Liardo L, Tozzi A, Mancosu P, Tomatis S, Cozzi L, Scorsetti M, Alongi, F, Iftode, C, Arcangeli, S, Villa, E, Liardo, L, Tozzi, A, Mancosu, P, Tomatis, S, Cozzi, L, Scorsetti, M, Alongi F, Iftode C, Arcangeli S, Villa E, Liardo L, Tozzi A, Mancosu P, Tomatis S, Cozzi L, and Scorsetti M

Published
2013

35. EP-1296: Adjuvant radiotherapy in endometrial cancer: Volumetric Modulated Intensity Arc Therapy vs 3DRT

Author

Iftode, C., primary, Tozzi, A., additional, Clerici, E., additional, Di Brina, L., additional, D'Agostino, G.R., additional, Ascolese, A.M., additional, Comito, T., additional, Franceschini, D., additional, Franzese, C., additional, De Rose, F., additional, Tomatis, S., additional, Mancosu, P., additional, Navarria, P., additional, and Scorsetti, M., additional

Published
2017
Full Text
View/download PDF

36. EP-1337: High hypofractionation using beacon transponders in intermediate-risk prostate cancer: first results

Author

Di Brina, L., primary, D'agostino, G., additional, Franzese, C., additional, Franceschini, D., additional, Comito, T., additional, De Rose, F., additional, Navarria, P., additional, Tozzi, A., additional, Iftode, C., additional, Ascolese, A., additional, Clerici, E., additional, Pasini, L., additional, Benetti, A., additional, and Scorsetti, M., additional

Published
2017
Full Text
View/download PDF

39. EP-1343: Is stereotactic body radiation therapy a viable option for elderly patients with prostate cancer?

Author

Franzese, C., primary, D'agostino, G., additional, Di Brina, L., additional, Cozzi, L., additional, Comito, T., additional, Franceschini, D., additional, De Rose, F., additional, Navarria, P., additional, Clerici, E., additional, Ascolese, A., additional, Tozzi, A., additional, Iftode, C., additional, Tomatis, S., additional, and Scorsetti, M., additional

Published
2017
Full Text
View/download PDF

40. EP-1170: Hypofractionated radiotherapy for ductal carcinoma in situ using VMAT: acute toxicity and cosmesis

Author

De Rose, F., primary, Fogliata, A., additional, Franceschini, D., additional, Iftode, C., additional, Ascolese, A.M., additional, Comito, T., additional, Di Brina, L., additional, Tozzi, A., additional, Franzese, C., additional, Clerici, E., additional, D’Agostino, G.R., additional, Navarria, P., additional, Lobefalo, F., additional, and Scorsetti, M., additional

Published
2017
Full Text
View/download PDF

41. Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study

Author

Comito, T., primary, Cozzi, L., additional, Zerbi, A., additional, Franzese, C., additional, Clerici, E., additional, Tozzi, A., additional, Iftode, C., additional, Navarria, P., additional, D'Agostino, G., additional, Fogliata, A., additional, Mancosu, P., additional, Tomatis, S., additional, Carnaghi, C., additional, Personeni, N., additional, Santoro, A., additional, and Scorsetti, M., additional

Published
2017
Full Text
View/download PDF

44. Is There a Role for Stereotactic Body Radiation Therapy (SBRT) in Oligometastatic Breast Cancer? Results From an Observational Study

Author

De Rose, F., primary, Franceschini, D., additional, Cozzi, L., additional, Comito, T., additional, D'Agostino, G.R., additional, Navarria, P., additional, Ascolese, A.M., additional, Tozzi, A., additional, Iftode, C., additional, Franzese, C., additional, Clerici, E., additional, Tomatis, S., additional, Fogliata, A., additional, and Scorsetti, M., additional

Published
2016
Full Text
View/download PDF

45. Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study

Author

Comito, Tiziana, primary, Cozzi, L., additional, Clerici, E., additional, Franzese, C., additional, Tozzi, A., additional, Iftode, C., additional, Navarria, P., additional, D’Agostino, G., additional, Rimassa, L., additional, Carnaghi, C., additional, Personeni, N., additional, Tronconi, M. C., additional, De Rose, F., additional, Franceschini, D., additional, Ascolese, A. M., additional, Fogliata, A., additional, Tomatis, S., additional, Santoro, A., additional, Zerbi, A., additional, and Scorsetti, M., additional

Published
2016
Full Text
View/download PDF

46. PO-0654: Hypofractionated StereotaticRS for patients with brain metastases. Outcome evaluation and toxicity

Author

Navarria, P., primary, Ascolese, A., additional, D'agostino, G., additional, Villa, E., additional, Clerici, E., additional, Tozzi, A., additional, Iftode, C., additional, De Rose, F., additional, Liardo, L., additional, Comito, T., additional, Franzese, C., additional, Franceschini, D., additional, Pessina, F., additional, Riva, M., additional, Bello, L., additional, Reggiori, G., additional, and Scorsetti, M., additional

Published
2016
Full Text
View/download PDF

47. EP-1443: Radical hypofractionated VMAT-RA for stage III NSCLC in the elderly: feasibility and toxicity

Author

Ascolese, A.M., primary, Franceschini, D., additional, De rose, F., additional, Cozzi, L., additional, Navarria, P., additional, Tozzi, A., additional, Iftode, C., additional, Villa, E., additional, Franzese, C., additional, Comito, T., additional, D'agostino, G., additional, Tomatis, S., additional, Liardo, L., additional, and Scorsetti, M., additional

Published
2016
Full Text
View/download PDF

48. PV-0511: Hypofractionated VMAT for early stage breast cancer: acute toxicity and cosmesis in 840 patients

Author

Iftode, C., primary, De Rose, F., additional, Franceschini, D., additional, Fogliata, A., additional, Villa, E., additional, Ascolese, A.M., additional, Navarria, P., additional, D'Agostino, G.R., additional, Franzese, C., additional, Comito, T., additional, Tozzi, A., additional, Clerici, E., additional, Liardo, R.L.E., additional, Stravato, A., additional, and Scorsetti, M., additional

Published
2016
Full Text
View/download PDF

49. EP-1442: Oligometastatic colorectal cancer in elderly patients: role of stereotactic body radiation therapy

Author

Franceschini, D., primary, Clerici, E., additional, Cozzi, L., additional, Tozzi, A., additional, Iftode, C., additional, Franzese, C., additional, Comito, T., additional, De Rose, F., additional, Navarria, P., additional, D'Agostino, G.R., additional, Villa, E., additional, Rocco Luca, L., additional, Ascolese, A.M., additional, Zucconi, F., additional, and Scorsetti, M., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results